Ajanta Pharma

Buy Ajanta Pharma; target of Rs 3200: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3200 in its research report dated September 19, 2025.

Trade Spotlight: How should you trade Bayer Cropscience, Jindal Stainless, General Insurance Corp, HUL, Bharti Hexacom, JSW Steel and others on August 1?

The bearish sentiment is expected to prevail until the frontline indices provide a sustainable close above the medium-term moving average. Below are some short-term trading ideas to consider.

Ajanta Pharma Consolidated June 2025 Net Sales at Rs 1,302.65 crore, up 13.78% Y-o-Y

Ajanta Pharma Standalone June 2025 Net Sales at Rs 1,208.56 crore, up 12.19% Y-o-Y

Trade Spotlight: How should you trade Ajanta Pharma, Hyundai Motor India, Max Healthcare Institute, Nelcast, Cera Sanitaryware and others on June 13?

The market may attempt a rebound amid likely range-bound trading in the upcoming session, but the sustainability is the key watch. Below are some short-term trading ideas to consider.

Reduce Ajanta Pharma: target of Rs 2500: ICICI Securities

ICICI Securities recommended reduce rating on Ajanta Pharma with a target price of Rs 2,500 in its research report dated May 01, 2025.

Ajanta Pharma Consolidated March 2025 Net Sales at Rs 1,170.41 crore, up 11.04% Y-o-Y

Ajanta Pharma Standalone March 2025 Net Sales at Rs 1,013.94 crore, up 9.49% Y-o-Y

Buy Ajanta Pharma; target of Rs 3180: Choice Equity Broking

Choice Equity Broking is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3180 in its research report dated May 02, 2025.

Buy Ajanta Pharma; target of Rs 3260: Motilal Oswal

Motilal Oswal is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 3260 in its research report dated April 30, 2025.

Ajanta Pharma shares gain 10%, hit six-week high on surging volumes

Ajanta Pharma share price: The company reported an 11 percent rise in net profit for the December 2024 quarter, reaching Rs 233 crore, up from Rs 210 crore a year ago.

Trade Spotlight: How should you trade Tech Mahindra, Zomato, Ajanta Pharma, IndiGo, JSW Steel, and others on February 19?

Rangebound trading is expected to continue in the upcoming sessions amid elevated volatility. Below are some trading ideas for the near term.

Buy Ajanta Pharma; target of Rs 3220: Motilal Oswal

Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3220 in its research report dated January 30, 2025.

Ajanta Pharma Consolidated December 2024 Net Sales at Rs 1,146.13 crore, up 3.71% Y-o-Y

Ajanta Pharma Standalone December 2024 Net Sales at Rs 1,101.92 crore, up 1.53% Y-o-Y

Stocks to Watch Today: Larsen and Toubro, Wipro, PB Fintech, Biocon, IRCON, Kalyan Jewellers, Shree Cement, Tata Consumer in focus on 31 January

Stocks To Watch, Jan 31: Stocks like Bajaj Holdings & Investment, Container Corporation of India, Prestige Estates Projects, Greenlam Industries, Phoenix Mills, Jindal Steel & Power, Bank of Baroda, Astral, Praj Industries, Navin Fluorine International, Ajanta Pharma, JSW Steel, Torrent Power, and Western Carriers will be in focus on January 31.

Ajanta Pharma Consolidated September 2024 Net Sales at Rs 1,186.64 crore, up 15.38% Y-o-Y

Buy Ajanta Pharma; target of Rs 3470: Motilal Oswal

Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3470 in its research report dated October 28, 2024.

Stock Radar: Bharti Airtel, Adani Power, Suzlon, Federal Bank, Quess Corp, Genesys International in focus on Tuesday

Stocks like JSW Infrastructure, Tata Technologies, Spandana Sphoorty Financial, Kalpataru Projects International, Indraprastha Gas, Restaurant Brands Asia, Ajanta Pharma, Pfizer, and Tamilnad Mercantile Bank will also be in focus on October 29.

Buy Ajanta Pharma; target of Rs 2935: Motilal Oswal

Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 2935 in its research report dated July 30, 2024.

Ajanta Pharma Standalone June 2024 Net Sales at Rs 1,077.27 crore, up 6.18% Y-o-Y

Ajanta Pharma Consolidated March 2024 Net Sales at Rs 1,054.08 crore, up 19.53% Y-o-Y

Buy Ajanta Pharma; target of Rs 2,565: Motilal Oswal

Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 2,565 in its research report dated May 02, 2024.

Ajanta Pharma Standalone March 2024 Net Sales at Rs 926.07 crore, up 9.1% Y-o-Y

Ajanta Pharma shares zoom 14% on stellar Q4 earnings, buyback plans

Ajanta Pharma approved its fourth buyback plan in as many years, offering a premium of 25 percent to stakeholders.